Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.35657 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Altering phosphorylation of dystrophin S3059 to attenuate cancer cachexia.
Life Sci
December 2024
Centre for Muscle Research, Department of Anatomy and Physiology, The University of Melbourne, VIC 3010, Australia. Electronic address:
Aims: Cancer cachexia affects up to 80 % of patients with advanced cancer and accounts for >20 % of all cancer-related deaths. Sarcolemmal localization of dystrophin, a key protein within the dystrophin-glycoprotein complex (DGC), is perturbed in multiple muscle wasting conditions, including cancer cachexia, indicating a potential role for dystrophin in the maintenance of muscle mass. Strategies to preserve dystrophin expression at the sarcolemma might therefore combat muscle wasting.
View Article and Find Full Text PDFLow-molecular-weight polyphenol promotes cell sensitivity to cisplatin and alleviates cancer-related muscle atrophy via NF-κB suppression in oral squamous cell carcinoma.
J Oral Biosci
December 2024
Department of Life Sciences, National Cheng Kung University, Tainan, Taiwan R.O.C; Marine Biology and Cetacean Research Center, National Cheng Kung University, Tainan, Taiwan R.O.C. Electronic address:
Objective: Drug resistance and subsequent adverse effects, such as cancer cachexia, limit the clinical use of cisplatin. Oligonol® (Olg), a low-molecular-weight polyphenol, exhibits NF-κB inhibitory properties. NF-κB activation has been implicated in cisplatin resistance of cancer cells and skeletal muscle wasting.
View Article and Find Full Text PDFPharmacokinetics, Pharmacodynamics and Bioavailability of ACM-001.1 (S-Pindolol Benzoate) in Healthy Volunteers.
J Cachexia Sarcopenia Muscle
February 2025
Quotient Sciences, Nottingham, UK.
Background: S-pindolol has metabolic effects of potential benefit in cancer cachexia: reduced catabolism through nonselective β-blockade; increased anabolism through partial β2 receptor agonism; and increased appetite and reduced fatigue through central 5-hydroxytryptamine/serotonin receptor activity. A Phase 2a clinical trial demonstrated that S-pindolol can reverse weight loss and improve fat-free mass in patients with cancer-related weight loss. A comparative phase I bioavailability study of S-pindolol and racemic pindolol was performed to support the development of S-pindolol in cancer cachexia.
View Article and Find Full Text PDFAn international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN study.
Eur J Cancer
January 2025
Medical Oncology Unit, Sant'Andrea Hospital, Rome, Italy. Electronic address:
Background: Medical cannabis (MC) has gained traction in oncology for managing cancer-related symptoms, but its integration faces challenges due to limited evidence, inconsistent guidelines, and varied legal frameworks.
Methods: The TASMAN study aimed to assess the knowledge, attitudes, and practices of oncologists and palliative care providers globally regarding MC use in cancer care. A survey of healthcare providers from diverse regions and income levels was conducted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!